Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.

MLA

Elías, Esteban Enrique, et al. “Autologous T-Cell Activation Fosters ABT-199 Resistance in Chronic Lymphocytic Leukemia: Rationale for a Combined Therapy with SYK Inhibitors and Anti-CD20 Monoclonal Antibodies.” Haematologica, vol. 103, no. 10, Oct. 2018, pp. e458–61. EBSCOhost, https://doi.org/10.3324/haematol.2018.188680.

APA

Elías, E. E., Almejún, M. B., Colado, A., Cordini, G., Vergara-Rubio, M., Podaza, E., Risnik, D., Cabrejo, M., Fernández-Grecco, H., Bezares, R. F., Custidiano, M. D. R., Sánchez-Ávalos, J. C., Vicente, Á., Garate, G. M., Borge, M., Giordano, M., & Gamberale, R. (2018). Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. Haematologica, 103(10), e458–e461. https://doi.org/10.3324/haematol.2018.188680

Chicago

Elías, Esteban Enrique, María Belén Almejún, Ana Colado, Gregorio Cordini, Maricef Vergara-Rubio, Enrique Podaza, Denise Risnik, et al. 2018. “Autologous T-Cell Activation Fosters ABT-199 Resistance in Chronic Lymphocytic Leukemia: Rationale for a Combined Therapy with SYK Inhibitors and Anti-CD20 Monoclonal Antibodies.” Haematologica 103 (10): e458–61. doi:10.3324/haematol.2018.188680.